康希诺(688185.SH)：吸入用结核病加强疫苗于印度尼西亚启动I期临床试验并完成首例受试者入组

Core Viewpoint - The company, CanSino (688185.SH), has initiated Phase I clinical trials for its inhaled tuberculosis vaccine in Indonesia, marking a significant step in its vaccine development efforts [1] Group 1: Clinical Trial Details - The Phase I clinical trial aims to explore the safety and immunogenicity of a single dose of the inhaled tuberculosis vaccine (Ad5 vector) in adults aged 18-49 [1]